Wheeler Bio, an innovative contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of antibody-based therapies, announced the closing of an oversubscribed Series A-1 financing round. The $35 million round was led by Alloy Therapeutics and Echo Investment Capital (Echo), with participation from Mitsubishi Corporation (Americas), Germin8 Ventures, and Russell Westbrook Enterprises.
Westbrook shared about the investment on LinkedIn: “Thrilled to share that Russell Westbrook Enterprises is making an investment in Wheeler Bio, Inc.
Excited to support Wheeler Bio as they expand their capabilities in antibody-based therapy development. This round will drive the construction of a new 52,000 sq. ft. manufacturing facility and biomanufacturing workforce training center in Oklahoma City.
Love seeing the continued growth in the place I still call home. Just the beginning.”
